Malignant behaviorial characteristics of CD133+/- glioblastoma cells from a Northern Chinese population

Liu,Xiaozhi; Chen,Lei; Jiang,Zhongmin; Wang,Junfei; Su,Zhiguo; Li,Gang; Yu,Shizhu; Liu,Zhenlin

doi:10.3892/etm.2012.747

Malignant behaviorial characteristics of CD133+/- glioblastoma cells from a Northern Chinese population

Authors:
- Xiaozhi Liu
- Lei Chen
- Zhongmin Jiang
- Junfei Wang
- Zhiguo Su
- Gang Li
- Shizhu Yu
- Zhenlin Liu
View Affiliations

Affiliations: Department of Neurosurgery, Tianjin Binhai Neurological Institute, The Fifth Central Hospital of Tianjin, Tianjin, P.R. China , Department of Pathology, The Fifth Central Hospital of Tianjin, Tianjin, P.R. China, Department of Neuropathology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, P.R. China
Published online on: October 15, 2012 https://doi.org/10.3892/etm.2012.747
Pages: 65-72

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Following emergence of the tumor stem cell theory, the increasing number of related studies demonstrates the theory's growing importance in cancer research and its potential for clinical applications. Few studies have addressed the in vitro or in vivo properties of glioma stem cells from a Han Chinese population. In the present study, surgically obtained glioblastoma tissue was classified into two subtypes, CD133+ and CD133-. The hierarchy, invasiveness, growth tolerance under low nutrient conditions and colony forming abilities of the tissue samples were analyzed. Additionally, the characteristics of tumor cells transplanted subcutaneously or re‑transplanted into nude mice were observed. The results demonstrated that CD133+ glioblastoma cells derived from Han Chinese glioma specimens were more prone to primitive cell differentiation and more invasive than CD133- glioblastoma cells, leading to increased tumor malignancy compared with CD133- cells. The tumor formation rates of CD133+ and CD133- cells in mice were 26/30 and 2/30, respectively. A comparison of tumor subtypes demonstrated that CD133+ glioblastoma cells had a lower incidence of cell apoptosis in the tumor tissue and higher protein expression levels of Oct4, Sox2, PCNA, EGFR, Ang2, MMP2 and MMP9 compared with CD133- cells. Flow cytometry revealed that in the CD133+ and CD133- glioblastoma cell‑induced tumors, the percentage of CD133+ cells was 2.47±0.67 and 0.44±0.14%, respectively. The tumor formation rates following the re‑transplantation of CD133+ or CD133- tumors into nude mice were 10/10 and 4/10, respectively. These findings suggest that the CD133+ glioblastoma cell subpopulation has a stronger malignant cell phenotype than the CD133- subpopulation and that its recurrence rate is increased compared with the primitive tumorigenic rate following in vivo transplantation.

View Figures

View References

1	Gilbert MR: Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. Semin Oncol. 38(Suppl 4): S21–S33. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kesari S: Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Semin Oncol. 38(Suppl 4): S2–S10. 2011. View Article : Google Scholar : PubMed/NCBI
3	Borodovsky A, Seltzer MJ and Riggins GJ: Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Curr Opin Oncol. 24:83–89. 2012. View Article : Google Scholar : PubMed/NCBI
4	Navajas A and Giralt J: Evidence in medulloblastomas. Clin Transl Oncol. 12:271–277. 2010. View Article : Google Scholar : PubMed/NCBI
5	Pollina EA and Brunet A: Epigenetic regulation of aging stem cells. Oncogene. 30:3105–3126. 2011. View Article : Google Scholar : PubMed/NCBI
6	Endersby R and Baker SJ: PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene. 27:5416–5430. 2008. View Article : Google Scholar : PubMed/NCBI
7	Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
8	Sanchez-Martin M: Brain tumour stem cells: implications for cancer therapy and regenerative medicine. Curr Stem Cell Res Ther. 3:197–207. 2008. View Article : Google Scholar : PubMed/NCBI
9	Taylor RA and Risbridger GP: Prostatic tumor stroma: a key player in cancer progression. Curr Cancer Drug Targets. 8:490–497. 2008. View Article : Google Scholar : PubMed/NCBI
10	Mao XG, Zhang X and Zhen HN: Progress on potential strategies to target brain tumor stem cells. Cell Mol Neurobiol. 29:141–155. 2009. View Article : Google Scholar : PubMed/NCBI
11	Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI
12	Toda M: Therapeutic strategies targeting brain tumor stem cells. Brain Nerve. 61:799–803. 2009.(In Japanese).
13	Hide T and Kuratsu J: Progress in the study of brain tumor stem cells as treatment targets. Brain Nerve. 61:781–789. 2009.(In Japanese).
14	Binello E and Germano IM: Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci. 102:1958–1966. 2011. View Article : Google Scholar : PubMed/NCBI
15	Nicolis SK: Cancer stem cells and ‘stemness’ genes in neuro-oncology. Neurobiol Dis. 25:217–229. 2007.
16	Nakano I and Saya H: Cancer stem cells in malignant glioma - the mechanism of cancer initiation and the therapeutic development. No Shinkei Geka. 38:879–889. 2010.(In Japanese).
17	Zimmerman AL and Wu S: MicroRNAs, cancer and cancer stem cells. Cancer Lett. 300:10–19. 2011. View Article : Google Scholar : PubMed/NCBI
18	Qu Q and Shi Y: Neural stem cells in the developing and adult brains. J Cell Physiol. 221:5–9. 2009. View Article : Google Scholar : PubMed/NCBI
19	Singh SK, Clarke ID, Hide T and Dirks PB: Cancer stem cells in nervous system tumors. Oncogene. 23:7267–7273. 2004. View Article : Google Scholar : PubMed/NCBI
20	Dell’Albani P: Stem cell markers in gliomas. Neurochem Res. 33:2407–2415. 2008.
21	Pilkington GJ: Cancer stem cells in the mammalian central nervous system. Cell Prolif. 38:423–433. 2005. View Article : Google Scholar : PubMed/NCBI
22	Xie Z: Brain tumor stem cells. Neurochem Res. 34:2055–2066. 2009. View Article : Google Scholar : PubMed/NCBI
23	Yamamoto N, Tsuchiya H and Hoffman RM: Tumor imaging with multicolor fluorescent protein expression. Int J Clin Oncol. 16:84–91. 2011. View Article : Google Scholar : PubMed/NCBI
24	Sun H and Zhang S: Arsenic trioxide regulates the apoptosis of glioma cell and glioma stem cell via down-regulation of stem cell marker Sox2. Biochem Biophys Res Commun. 410:692–697. 2011. View Article : Google Scholar : PubMed/NCBI
25	Du Z, Jia D, Liu S, et al: Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia. 57:724–733. 2009. View Article : Google Scholar : PubMed/NCBI
26	Ferletta M, Caglayan D, Mokvist L, et al: Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells. Int J Cancer. 129:45–60. 2011. View Article : Google Scholar : PubMed/NCBI
27	Ischenko I, Seeliger H, Schaffer M, et al: Cancer stem cells: how can we target them? Curr Med Chem. 15:3171–3184. 2008. View Article : Google Scholar : PubMed/NCBI
28	Liu XS, Chopp M, Zhang RL, et al: Angiopoietin 2 mediates the differentiation and migration of neural progenitor cells in the subventricular zone after stroke. J Biol Chem. 284:22680–22689. 2009. View Article : Google Scholar : PubMed/NCBI
29	Amălinei C, Căruntu ID, Giuşcă SE and Bălan RA: Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol. 51:215–228. 2010.
30	Velinov N, Poptodorov G, Gabrovski N and Gabrovski S: The role of matrix metalloproteinases in the tumor growth and metastasis. Khirurgiia (Sofia). 1:44–49. 2010.(In Bulgarian).